EurekaMag
+ Translate
+ Most Popular
Gaucher's disease;thirty-two years experience at Siriraj Hospital
A study of Macrobathra Meyrick from China (Lepidoptera, Cosmopterigidae)
First occurrence in ores of tetragonal chalcocite
Effects of trace element nutrition on sleep patterns in adult women
N.Z. range management guidelines. 2. Design of grazing management systems for tussock country
A case of lipoma of the esophagus
A revision of world Acanthosomatidae (Heteroptera: Pentatomidae): keys to and descriptions of subfamilies, tribes and genera, with designation of types
Life history of the coronate scyphozoan Linuche unguiculata (Swartz, 1788)
Perceptual restoration of obliterated sounds
Mutagenicity studies on two chromium(III) coordination compounds
The formation of the skeleton. I. Growth of a long bone. 1st appearance of a center of calcification
Leucopenia and abnormal liver function in travellers on malaria chemoprophylaxis
The joint commission: four key root causes loom large in sentinel event data
Treatment of vitiligo with topical 15% lactic acid solution in combination with ultra violet-A
Behaviour of dairy cows within three hours after feed supply: I. Influence of housing type and time elapsing after feed supply
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Management and control of patients with type 2 diabetes mellitus in Lebanon: results from the International Diabetes Management Practices Study (IDMPS)
The diet composition and nutritional knowledge of patients with anorexia nervosa
Physoporella croatica Herak, 1958 of the Slovak karst Anisian (Slovakia, the West Carpathians Mts.)
Bright lights, big noise. How effective are vehicle warning systems?
Ein Plesiosaurier-Rest mit Magensteinen aus mittlerem Lias von Quedlinburg
Incidence of Chlamydia trachomatis in patients with sterility
Monster soup: the microscope and Victorian fantasy
Preliminary tests with residual sprays against poultry lice
Duration of the life of plants in phylogeny

Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis


Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis



Obstetrics and Gynecology 114(2 Part 1): 354-364



ISSN/ISBN: 0029-7844

PMID: 19622997

DOI: 10.1097/aog.0b013e3181ae98c2

To review the evidence regarding neuroprotective effects of antenatal exposure to magnesium sulfate. We conducted database searches of MEDLINE, the Cochrane Library and Controlled Trials Register, as well as the ClinicalTrials.gov and International Clinical Trials Register websites. Bibliographies of all relevant articles were reviewed. Randomized controlled trials comparing magnesium sulfate with placebo/other treatment in patients at risk of preterm delivery were evaluated for inclusion and methodological quality. The primary outcome was death or cerebral palsy by 18-24 months corrected age. Secondary outcomes were death, cerebral palsy, moderate-severe cerebral palsy, and death or moderate-severe cerebral palsy. Separate analyses were performed according to the gestational age (GA) at randomization (less than 32 to 34 weeks and less than 30 weeks) and for studies in which magnesium sulfate was used exclusively for fetal neuroprotection. Five randomized controlled trials were included (5,235 fetuses/infants). When analyzed by GA at randomization, in utero exposure to magnesium sulfate at less than 32-34 weeks did not reduce the rate of death or cerebral palsy (relative risk [RR] 0.92, 95% confidence interval [CI] 0.83-1.03). However, cerebral palsy (RR 0.70, 95% CI 0.55-0.89), moderate-severe cerebral palsy (RR 0.60, 95% CI 0.43-0.84), and death or moderate-severe cerebral palsy were significantly reduced, without an evident increase in the risk of death (RR 1.01, 95% CI 0.89-1.14). Similar results were obtained when the GA at randomization was less than 30 weeks. When only neuroprotection trials (four trials, 4,324 fetuses/infants) are analyzed, in utero exposure to magnesium sulfate additionally reduced the primary outcome of death or cerebral palsy. The number needed to treat to prevent one case of cerebral palsy among those who survive until age 18-24 months is 46 (95% CI 26-187) in infants exposed to magnesium sulfate in utero before 30 weeks, and 56 (95% CI 34-164) in infants exposed to magnesium sulfate in utero before 32 to 34 weeks. Fetal exposure to magnesium sulfate in women at risk of preterm delivery significantly reduces the risk of cerebral palsy without increasing the risk of death.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052855802

Download citation: RISBibTeXText

Related references

Effects of Antenatal Exposure to Magnesium Sulfate on Neuroprotection and Mortality in Preterm Infants: A Meta-analysis. Obstetrics and Gynecology (New York 1953) 114(2): 354-364, 2009

Antenatal exposure to magnesium sulfate and neuroprotection in preterm infants. Obstetrics and Gynecology Clinics of North America 38(2): 351-66 Xi, 2011

Implementation of an antenatal magnesium sulfate protocol for fetal neuroprotection in preterm infants. Scientific Reports 5: 14732, 2015

Antenatal Magnesium Sulfate Exposure and Ponderal Index in Preterm Infants. American Journal of Perinatology 36(3): 329-334, 2019

Antenatal magnesium sulfate exposure and acute cardiorespiratory events in preterm infants. American Journal of Obstetrics and Gynecology 212(1): 94.E1-94.E7, 2015

Antenatal Magnesium Sulfate Exposure and Acute Cardiorespiratory Events in Preterm Infants. Obstetric Anesthesia Digest 35(4): 203-204, 2015

Antenatal Magnesium Sulfate for Neuroprotection Before Preterm Birth?. Obstetric Anesthesia Digest 29(2): 83-84, 2009

Antenatal magnesium sulfate for neuroprotection before preterm birth?. New England Journal of Medicine 359(9): 962-964, 2008

Neuroprotection for preterm infants with antenatal magnesium sulphate. Journal de Gynecologie Obstetrique et Biologie de la Reproduction 45(10): 1418-1433, 2016

Effects of antenatal magnesium sulfate and corticosteroid therapy on sleep states of preterm infants. Research in Nursing and Health 29(4): 269-280, 2006

The use of antenatal magnesium sulfate for neuroprotection for infants born prematurely. F1000 Medicine Reports 2: 78, 2010

Antenatal Magnesium Sulfate for Preterm Neuroprotection: a Single-Center Experience from Kuwait Tertiary NICU. Biomedicine Hub 7(2): 80-87, 2022

Comparison of the effects of antenatal magnesium sulphate and ritodrine exposure on circulatory adaptation in preterm infants. Clinical Physiology and Functional Imaging 22(1): 13-17, 2002

Combined Use of Magnesium Sulfate and Fingolimod for Antenatal Neuroprotection against Inflammation-Mediated Experimental Preterm Brain Injury in a Rat Model. Fetal and Pediatric Pathology 2021: 1-13, 2021

Early cerebral neuroprotection by maternally-administered magnesium sulfate in preterm infants is related to initial post-natal serum magnesium levels. Pediatric Research 39(4 Part 2): 253A, 1996